Genetically engineered mouse models of prostate cancer

Molecular Oncology

Volumn 7, Issue 2, 2013, Pages 190-205

  Parisotto, Maxime ^a   Metzger, Daniel ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Androgen; Conditional somatic mutagenesis; Cre; Knock out; Stem cells; Transgenic

Indexed keywords

ANDROGEN RECEPTOR; EARLY GROWTH RESPONSE FACTOR 1; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PROBASIN; PROSTATEIN; RECOMBINASE; TUMOR SUPPRESSOR PROTEIN;

CANCER GROWTH; CARCINOGENESIS; EXPERIMENTAL MOUSE; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; INVASIVE CARCINOMA; KNOCKOUT MOUSE; METASTASIS; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; REVIEW; SEMINAL VESICLE; SOMATIC MUTATION; SQUAMOUS CELL METAPLASIA; STEM CELL TRANSPLANTATION; TRANSCRIPTION REGULATION; TRANSGENE; TRANSGENIC MOUSE;

MUS;

EID: 84875808870     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.005     Document Type: Review

References (166)

1. Abate-Shen C., Banach-Petrosky W.A., Sun X., Economides K.D., Desai N., Gregg J.P., Borowsky A.D., Cardiff R.D., Shen M.M. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 2003, 63:3886-3890.
2. Abdulkadir S.A., Magee J.A., Peters T.J., Kaleem Z., Naughton C.K., Humphrey P.A., Milbrandt J. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 2002, 22:1495-1503.
3. Abdulkadir S.A., Qu Z., Garabedian E., Song S.K., Peters T.J., Svaren J., Carbone J.M., Naughton C.K., Catalona W.J., Ackerman J.J., Gordon J.I., Humphrey P.A., Milbrandt J. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat. Med. 2001, 7:101-107.
4. Acevedo V.D., Gangula R.D., Freeman K.W., Li R., Zhang Y., Wang F., Ayala G.E., Peterson L.E., Ittmann M., Spencer D.M. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007, 12:559-571.
5. Ahmad I., Sansom O.J., Leung H.Y. Advances in mouse models of prostate cancer. Expert Rev. Mol. Med. 2008, 10:e16.
6. Akhtar F.Z., Garabrant D.H., Ketchum N.S., Michalek J.E. Cancer in US air force veterans of the Vietnam war. J. Occup. Environ. Med. 2004, 46:123-136.
7. Allison J., Zhang Y.L., Parker M.G. Tissue-specific and hormonal regulation of the gene for rat prostatic steroid-binding protein in transgenic mice. Mol. Cell. Biol. 1989, 9:2254-2257.
8. Backman S.A., Ghazarian D., So K., Sanchez O., Wagner K.U., Hennighausen L., Suzuki A., Tsao M.S., Chapman W.B., Stambolic V., Mak T.W. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1725-1730.
9. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., Kim M., Desai N., Young P., Norton C.R., Gridley T., Cardiff R.D., Cunha G.R., Abate-Shen C., Shen M.M. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999, 13:966-977.
10. Bierie B., Nozawa M., Renou J.P., Shillingford J.M., Morgan F., Oka T., Taketo M.M., Cardiff R.D., Miyoshi K., Wagner K.U., Robinson G.W., Hennighausen L. Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 2003, 22:3875-3887.
11. Birbach A., Casanova E., Schmid J.A. A Probasin-MerCreMer BAC allows inducible recombination in the mouse prostate. Genesis 2009, 47:757-764.
12. Bosland M.C., Prinsen M.K. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2'-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res. 1990, 50:691-699.
13. Bostwick D.G. Prostatic intraepithelial neoplasia (PIN). Urology 1989, 34:16-22.
14. Bostwick D.G., Qian J. High-grade prostatic intraepithelial neoplasia. Mod. Pathol. 2004, 17:360-379.
15. Bowen C., Bubendorf L., Voeller H.J., Slack R., Willi N., Sauter G., Gasser T.C., Koivisto P., Lack E.E., Kononen J., Kallioniemi O.P., Gelmann E.P. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000, 60:6111-6115.
16. Branda C.S., Dymecki S.M. Talking about a revolution: the impact of site-specific recombinases on genetic analyses in mice. Dev. Cell. 2004, 6:7-28.
17. Bray F., Lortet-Tieulent J., Ferlay J., Forman D., Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur. J. Cancer 2010, 46:3040-3052.
18. Bruckheimer E.M., Brisbay S., Johnson D.J., Gingrich J.R., Greenberg N., McDonnell T.J. Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene 2000, 19:5251-5258.
19. Bruxvoort K.J., Charbonneau H.M., Giambernardi T.A., Goolsby J.C., Qian C.N., Zylstra C.R., Robinson D.R., Roy-Burman P., Shaw A.K., Buckner-Berghuis B.D., Sigler R.E., Resau J.H., Sullivan R., Bushman W., Williams B.O. Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res. 2007, 67:2490-2496.
20. Bubendorf L., Schopfer A., Wagner U., Sauter G., Moch H., Willi N., Gasser T.C., Mihatsch M.J. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 2000, 31:578-583.
21. Burri N., Shaw P., Bouzourene H., Sordat I., Sordat B., Gillet M., Schorderet D., Bosman F.T., Chaubert P. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab. Invest. 2001, 81:217-229.
22. Capecchi M.R. Targeted gene replacement. Sci. Am. 1994, 270:52-59.
23. Carver B.S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., Alimonti A., Nardella C., Varmeh S., Scardino P.T., Cordon-Cardo C., Gerald W., Pandolfi P.P. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 2009, 41:619-624.
24. Chen M.L., Xu P.Z., Peng X.D., Chen W.S., Guzman G., Yang X., Di Cristofano A., Pandolfi P.P., Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 2006, 20:1569-1574.
25. Chen Z., Carracedo A., Lin H.K., Koutcher J.A., Behrendt N., Egia A., Alimonti A., Carver B.S., Gerald W., Teruya-Feldstein J., Loda M., Pandolfi P.P. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci. Signal. 2009, 2:ra44.
26. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., Cordon-Cardo C., Pandolfi P.P. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
27. Chrisofos M., Papatsoris A.G., Lazaris A., Deliveliotis C. Precursor lesions of prostate cancer. Crit. Rev. Clin. Lab. Sci. 2007, 44:243-270.
28. Chung A.C., Zhou S., Liao L., Tien J.C., Greenberg N.M., Xu J. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res. 2007, 67:5965-5975.
29. Clegg N.J., Couto S.S., Wongvipat J., Hieronymus H., Carver B.S., Taylor B.S., Ellwood-Yen K., Gerald W.L., Sander C., Sawyers C.L. MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One 2011, 6:e17449.
30. Cleutjens K.B., van der Korput H.A., Ehren-van Eekelen C.C., Sikes R.A., Fasciana C., Chung L.W., Trapman J. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol. Endocrinol. 1997, 11:1256-1265.
31. Cunha G.R., Donjacour A.A., Cooke P.S., Mee S., Bigsby R.M., Higgins S.J., Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr. Rev. 1987, 8:338-362.
32. Denmeade S.R., Isaacs J.T. A history of prostate cancer treatment. Nat. Rev. Cancer 2002, 2:389-396.
33. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 2001, 27:222-224.
34. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 1998, 19:348-355.
35. DiGiovanni J., Kiguchi K., Frijhoff A., Wilker E., Bol D.K., Beltran L., Moats S., Ramirez A., Jorcano J., Conti C. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3455-3460.
36. Ding Z., Wu C.J., Chu G.C., Xiao Y., Ho D., Zhang J., Perry S.R., Labrot E.S., Wu X., Lis R., Hoshida Y., Hiller D., Hu B., Jiang S., Zheng H., Stegh A.H., Scott K.L., Signoretti S., Bardeesy N., Wang Y.A., Hill D.E., Golub T.R., Stampfer M.J., Wong W.H., Loda M., Mucci L., Chin L., DePinho R.A. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
37. Ding Z., Wu C.J., Jaskelioff M., Ivanova E., Kost-Alimova M., Protopopov A., Chu G.C., Wang G., Lu X., Labrot E.S., Hu J., Wang W., Xiao Y., Zhang H., Zhang J., Gan B., Perry S.R., Jiang S., Li L., Horner J.W., Wang Y.A., Chin L., DePinho R.A. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012, 148:896-907.
38. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., Thomas G.V., Sawyers C.L. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003, 4:223-238.
39. Ellwood-Yen K., Wongvipat J., Sawyers C. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res. 2006, 66:10513-10516.
40. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46:765-781.
41. Fleming W.H., Hamel A., MacDonald R., Ramsey E., Pettigrew N.M., Johnston B., Dodd J.G., Matusik R.J. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res. 1986, 46:1535-1538.
42. Foster B.A., Evangelou A., Gingrich J.R., Kaplan P.J., DeMayo F., Greenberg N.M. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 2002, 70:624-632.
43. Freeman K.W., Welm B.E., Gangula R.D., Rosen J.M., Ittmann M., Greenberg N.M., Spencer D.M. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res. 2003, 63:8256-8263.
44. Fritz W.A., Lin T.M., Cardiff R.D., Peterson R.E. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 2007, 28:497-505.
45. Fritz W.A., Lin T.M., Moore R.W., Cooke P.S., Peterson R.E. In utero and lactational 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure: effects on the prostate and its response to castration in senescent C57BL/6J mice. Toxicol. Sci. 2005, 86:387-395.
46. Gao H., Ouyang X., Banach-Petrosky W., Borowsky A.D., Lin Y., Kim M., Lee H., Shih W.J., Cardiff R.D., Shen M.M., Abate-Shen C. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17204-17209.
47. Germann M., Wetterwald A., Guzman-Ramirez N., van der Pluijm G., Culig Z., Cecchini M.G., Williams E.D., Thalmann G.N. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 2012, 30:1076-1086.
48. Gingrich J.R., Barrios R.J., Kattan M.W., Nahm H.S., Finegold M.J., Greenberg N.M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 1997, 57:4687-4691.
49. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., Angelopoulou R., Rosen J.M., Greenberg N.M. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996, 56:4096-4102.
50. Glenney J.R. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J. Biol. Chem. 1989, 264:20163-20166.
51. Gounari F., Signoretti S., Bronson R., Klein L., Sellers W.R., Kum J., Siermann A., Taketo M.M., von Boehmer H., Khazaie K. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 2002, 21:4099-4107.
52. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:3439-3443.
53. Greenberg N.M., DeMayo F.J., Sheppard P.C., Barrios R., Lebovitz R., Finegold M., Angelopoulou R., Dodd J.G., Duckworth M.L., Rosen J.M., et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 1994, 8:230-239.
54. Grignon D.J. Unusual subtypes of prostate cancer. Mod. Pathol. 2004, 17:316-327.
55. Gu H., Marth J.D., Orban P.C., Mossmann H., Rajewsky K. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 1994, 265:103-106.
56. Guertin D.A., Stevens D.M., Saitoh M., Kinkel S., Crosby K., Sheen J.H., Mullholland D.J., Magnuson M.A., Wu H., Sabatini D.M. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009, 15:148-159.
57. Han G., Buchanan G., Ittmann M., Harris J.M., Yu X., Demayo F.J., Tilley W., Greenberg N.M. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1151-1156.
58. Hsieh C.L., Xie Z., Liu Z.Y., Green J.E., Martin W.D., Datta M.W., Yeung F., Pan D., Chung L.W. A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. J. Mol. Endocrinol. 2005, 35:293-304.
59. Huang J., Powell W.C., Khodavirdi A.C., Wu J., Makita T., Cardiff R.D., Cohen M.B., Sucov H.M., Roy-Burman P. Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res. 2002, 62:4812-4819.
60. Hubner A., Mulholland D.J., Standen C.L., Karasarides M., Cavanagh-Kyros J., Barrett T., Chi H., Greiner D.L., Tournier C., Sawyers C.L., Flavell R.A., Wu H., Davis R.J. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:12046-12051.
61. Iyer M., Salazar F.B., Lewis X., Zhang L., Wu L., Carey M., Gambhir S.S. Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res. 2005, 14:47-55.
62. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
63. Jenkins R.B., Qian J., Lieber M.M., Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997, 57:524-531.
64. Jiang M., Fernandez S., Jerome W.G., He Y., Yu X., Cai H., Boone B., Yi Y., Magnuson M.A., Roy-Burman P., Matusik R.J., Shappell S.B., Hayward S.W. Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell. Death Differ. 2010, 17:469-481.
65. Jiang Z.K., Sato M., Wei L.H., Kao C., Wu L. Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. Cancer Res. 2011, 71:6250-6260.
66. Jin C., McKeehan K., Wang F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate 2003, 57:160-164.
67. Kaplan-Lefko P.J., Chen T.M., Ittmann M.M., Barrios R.J., Ayala G.E., Huss W.J., Maddison L.A., Foster B.A., Greenberg N.M. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003, 55:219-237.
68. Kaplan-Lefko P.J., Sutherland B.W., Evangelou A.I., Hadsell D.L., Barrios R.J., Foster B.A., Demayo F., Greenberg N.M. Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis. Oncogene 2008, 27:2868-2876.
69. Kasper S. Stem cells: the root of prostate cancer?. J. Cell. Physiol. 2008, 216:332-336.
70. Kasper S., Rennie P.S., Bruchovsky N., Sheppard P.C., Cheng H., Lin L., Shiu R.P., Snoek R., Matusik R.J. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J. Biol. Chem. 1994, 269:31763-31769.
71. Kasper S., Sheppard P.C., Yan Y., Pettigrew N., Borowsky A.D., Prins G.S., Dodd J.G., Duckworth M.L., Matusik R.J. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab. Invest. 1998, 78:319-333.
72. Kasper S., Smith J.A. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J. Urol. 2004, 172:12-19.
73. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., Desai N., Wang Y., Hayward S.W., Cunha G.R., Cardiff R.D., Shen M.M., Abate-Shen C. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 2002, 62:2999-3004.
74. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2884-2889.
75. King J.C., Xu J., Wongvipat J., Hieronymus H., Carver B.S., Leung D.H., Taylor B.S., Sander C., Cardiff R.D., Couto S.S., Gerald W.L., Sawyers C.L. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 2009, 41:524-526.
76. Kiyokawa H., Kineman R.D., Manova-Todorova K.O., Soares V.C., Hoffman E.S., Ono M., Khanam D., Hayday A.C., Frohman L.A., Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996, 85:721-732.
77. Klein R.D. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research. Mutat. Res. 2005, 576:111-119.
78. Komiya A., Suzuki H., Imamoto T., Kamiya N., Nihei N., Naya Y., Ichikawa T., Fuse H. Neuroendocrine differentiation in the progression of prostate cancer. Int. J. Urol. 2009, 16:37-44.
79. Korsten H., Ziel-van der Made A., Ma X., van der Kwast T., Trapman J. Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS One 2009, 4:e5662.
80. Kurita T., Medina R.T., Mills A.A., Cunha G.R. Role of p63 and basal cells in the prostate. Development 2004, 131:4955-4964.
81. Kwabi-Addo B., Giri D., Schmidt K., Podsypanina K., Parsons R., Greenberg N., Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11563-11568.
82. Lang S.H., Frame F.M., Collins A.T. Prostate cancer stem cells. J. Pathol. 2009, 217:299-306.
83. Leong K.G., Wang B.E., Johnson L., Gao W.Q. Generation of a prostate from a single adult stem cell. Nature 2008, 456:804-808.
84. Liao C.P., Zhong C., Saribekyan G., Bading J., Park R., Conti P.S., Moats R., Berns A., Shi W., Zhou Z., Nikitin A.Y., Roy-Burman P. Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res. 2007, 67:7525-7533.
85. Liu J., Pascal L.E., Isharwal S., Metzger D., Ramos Garcia R., Pilch J., Kasper S., Williams K., Basse P.H., Nelson J.B., Chambon P., Wang Z. Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate. Mol. Endocrinol. 2011, 25:1849-1857.
86. Luchman H.A., Benediktsson H., Villemaire M.L., Peterson A.C., Jirik F.R. The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision. PLoS One 2008, 3:e3940.
87. Luchman H.A., Friedman H.C., Villemaire M.L., Peterson A.C., Jirik F.R. Temporally controlled prostate epithelium-specific gene alterations. Genesis 2008, 46:229-234.
88. Lyons S.K., Lim E., Clermont A.O., Dusich J., Zhu L., Campbell K.D., Coffee R.J., Grass D.S., Hunter J., Purchio T., Jenkins D. Noninvasive bioluminescence imaging of normal and spontaneously transformed prostate tissue in mice. Cancer Res. 2006, 66:4701-4707.
89. Ma X., Ziel-van der Made A.C., Autar B., van der Korput H.A., Vermeij M., van Duijn P., Cleutjens K.B., de Krijger R., Krimpenfort P., Berns A., van der Kwast T.H., Trapman J. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res. 2005, 65:5730-5739.
90. Maddison L.A., Nahm H., DeMayo F., Greenberg N.M. Prostate specific expression of Cre recombinase in transgenic mice. Genesis 2000, 26:154-156.
91. Majeed N., Blouin M.J., Kaplan-Lefko P.J., Barry-Shaw J., Greenberg N.M., Gaudreau P., Bismar T.A., Pollak M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 2005, 24:4736-4740.
92. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., Loda M., Lane H.A., Sellers W.R. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 2004, 10:594-601.
93. Majumder P.K., Yeh J.J., George D.J., Febbo P.G., Kum J., Xue Q., Bikoff R., Ma H., Kantoff P.W., Golub T.R., Loda M., Sellers W.R. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7841-7846.
94. Marker P.C., Donjacour A.A., Dahiya R., Cunha G.R. Hormonal, cellular, and molecular control of prostatic development. Dev. Biol. 2003, 253:165-174.
95. Maroulakou I.G., Anver M., Garrett L., Green J.E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:11236-11240.
96. Masumori N., Thomas T.Z., Chaurand P., Case T., Paul M., Kasper S., Caprioli R.M., Tsukamoto T., Shappell S.B., Matusik R.J. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 2001, 61:2239-2249.
97. McNeal J.E., Bostwick D.G. Intraductal dysplasia: a premalignant lesion of the prostate. Hum. Pathol. 1986, 17:64-71.
98. McNeal J.E., Bostwick D.G., Kindrachuk R.A., Redwine E.A., Freiha F.S., Stamey T.A. Patterns of progression in prostate cancer. Lancet 1986, 1:60-63.
99. Metzger D., Chambon P. Site- and time-specific gene targeting in the mouse. Methods 2001, 24:71-80.
100. Metzger D., Feil R. Engineering the mouse genome by site-specific recombination. Curr. Opin. Biotechnol. 1999, 10:470-476.
101. Montironi R., Mazzucchelli R., Lopez-Beltran A., Scarpelli M., Cheng L. Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. BJU Int. 2011, 108:1394-1401.
102. Mostaghel E.A., Page S.T., Lin D.W., Fazli L., Coleman I.M., True L.D., Knudsen B., Hess D.L., Nelson C.C., Matsumoto A.M., Bremner W.J., Gleave M.E., Nelson P.S. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007, 67:5033-5041.
103. Mulholland D.J., Tran L.M., Li Y., Cai H., Morim A., Wang S., Plaisier S., Garraway I.P., Huang J., Graeber T.G., Wu H. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011, 19:792-804.
104. Mulholland D.J., Xin L., Morim A., Lawson D., Witte O., Wu H. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res. 2009, 69:8555-8562.
105. Nacerddine K., Beaudry J.B., Ginjala V., Westerman B., Mattiroli F., Song J.Y., van der Poel H., Ponz O.B., Pritchard C., Cornelissen-Steijger P., Zevenhoven J., Tanger E., Sixma T.K., Ganesan S., van Lohuizen M. Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J. Clin. Invest. 2012, 122:1920-1932.
106. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D.Y. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720.
107. Nardella C., Carracedo A., Alimonti A., Hobbs R.M., Clohessy J.G., Chen Z., Egia A., Fornari A., Fiorentino M., Loda M., Kozma S.C., Thomas G., Cordon-Cardo C., Pandolfi P.P. Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci. Signal. 2009, 2:ra2.
108. Nastiuk K.L., Liu H., Hamamura M., Muftuler L.T., Nalcioglu O., Krolewski J.J. In vivo MRI volumetric measurement of prostate regression and growth in mice. BMC Urol. 2007, 7:12.
109. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
110. Niu Y., Altuwaijri S., Lai K.P., Wu C.T., Ricke W.A., Messing E.M., Yao J., Yeh S., Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12182-12187.
111. Niu Y., Altuwaijri S., Yeh S., Lai K.P., Yu S., Chuang K.H., Huang S.P., Lardy H., Chang C. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12188-12193.
112. Pearson H.B., Phesse T.J., Clarke A.R. K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res. 2009, 69:94-101.
113. Peehl D.M. Primary cell cultures as models of prostate cancer development. Endocr. Relat. Cancer 2005, 12:19-47.
114. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., Benson M.C., Small E.J., Raghavan D., Crawford E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351:1513-1520.
115. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1563-1568.
116. Pollard M., Luckert P.H., Snyder D.L. The promotional effect of testosterone on induction of prostate-cancer in MNU-sensitized L-W rats. Cancer Lett. 1989, 45:209-212.
117. Qi J., Nakayama K., Cardiff R.D., Borowsky A.D., Kaul K., Williams R., Krajewski S., Mercola D., Carpenter P.M., Bowtell D., Ronai Z.A. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 2010, 18:23-38.
118. Qian J., Jenkins R.B., Bostwick D.G. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod. Pathol. 1997, 10:1113-1119.
119. Rao V., Heard J.C., Ghaffari H., Wali A., Mutton L.N., Bieberich C.J. A Hoxb13-driven reverse tetracycline transactivator system for conditional gene expression in the prostate. Prostate 2012, 72:1045-1051.
120. Ratnacaram C.K., Teletin M., Jiang M., Meng X., Chambon P., Metzger D. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2521-2526.
121. Saez E., Olson P., Evans R.M. Genetic deficiency in Pparg does not alter development of experimental prostate cancer. Nat. Med. 2003, 9:1265-1266.
122. Sato K., Qian J., Slezak J.M., Lieber M.M., Bostwick D.G., Bergstralh E.J., Jenkins R.B. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer Inst. 1999, 91:1574-1580.
123. Schoder H., Larson S.M. Positron emission tomography for prostate, bladder, and renal cancer. Semin. Nucl. Med. 2004, 34:274-292.
124. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Paez A., Maattanen L., Bangma C.H., Aus G., Carlsson S., Villers A., Rebillard X., van der Kwast T., Kujala P.M., Blijenberg B.G., Stenman U.H., Huber A., Taari K., Hakama M., Moss S.M., de Koning H.J., Auvinen A. Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 2012, 366:981-990.
125. Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 1999, 9:22-30.
126. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24:1967-2000.
127. Shibata M.A., Jorcyk C.L., Liu M.L., Yoshidome K., Gold L.G., Green J.E. The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol. Pathol. 1998, 26:177-182.
128. Shim E.H., Johnson L., Noh H.L., Kim Y.J., Sun H., Zeiss C., Zhang H. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res. 2003, 63:1583-1588.
129. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62:220-241.
130. Singh P., Yam M., Russell P.J., Khatri A. Molecular and traditional chemotherapy: a united front against prostate cancer. Cancer Lett. 2010, 293:1-14.
131. Song Z., Wu X., Powell W.C., Cardiff R.D., Cohen M.B., Tin R.T., Matusik R.J., Miller G.J., Roy-Burman P. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 2002, 62:5096-5105.
132. Stambolic V., Tsao M.S., Macpherson D., Suzuki A., Chapman W.B., Mak T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 2000, 60:3605-3611.
133. Stanbrough M., Leav I., Kwan P.W., Bubley G.J., Balk S.P. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10823-10828.
134. Stanfel M.N., Moses K.A., Carson J.A., Zimmer D.B., DeMayo F., Schwartz R.J., Zimmer W.E. Expression of an Nkx3.1-CRE gene using ROSA26 reporter mice. Genesis 2006, 44:550-555.
135. Sternberg N., Hamilton D., Austin S., Yarmolinsky M., Hoess R. Site-specific recombination and its role in the life cycle of bacteriophage P1. Cold Spring Harb Symp. Quant Biol. 1981, 45(Pt 1):297-309.
136. Sutherland B.W., Knoblaugh S.E., Kaplan-Lefko P.J., Wang F., Holzenberger M., Greenberg N.M. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium. Cancer Res. 2008, 68:3495-3504.
137. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., Mak T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 1998, 8:1169-1178.
138. Takahashi S., Watanabe T., Okada M., Inoue K., Ueda T., Takada I., Watabe T., Yamamoto Y., Fukuda T., Nakamura T., Akimoto C., Fujimura T., Hoshino M., Imai Y., Metzger D., Miyazono K., Minami Y., Chambon P., Kitamura T., Matsumoto T., Kato S. Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4938-4943.
139. Tien J.C., Zhou S., Xu J. The role of SRC-1 in murine prostate cancinogenesis is nonessential due to a possible compensation of SRC-3/AIB1 overexpression. Int. J. Biol. Sci. 2009, 5:256-264.
140. Timms B.G. Prostate development: a historical perspective. Differentiation 2008, 76:565-577.
141. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., Yu J., Wang L., Montie J.E., Rubin M.A., Pienta K.J., Roulston D., Shah R.B., Varambally S., Mehra R., Chinnaiyan A.M. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
142. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., Cordon-Cardo C., Pandolfi P.P. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003, 1:E59.
143. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9:401-406.
144. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
145. Wagner K.U., McAllister K., Ward T., Davis B., Wiseman R., Hennighausen L. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res. 2001, 10:545-553.
146. Wang H., Xu Y., Fang Z., Chen S., Balk S.P., Yuan X. Doxycycline regulated induction of AKT in murine prostate drives proliferation independently of p27 cyclin dependent kinase inhibitor downregulation. PLoS One 2012, 7:e41330.
147. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., Thomas G.V., Li G., Roy-Burman P., Nelson P.S., Liu X., Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4:209-221.
148. Wang S., Garcia A.J., Wu M., Lawson D.A., Witte O.N., Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1480-1485.
149. Wang X., Kruithof-de Julio M., Economides K.D., Walker D., Yu H., Halili M.V., Hu Y.P., Price S.M., Abate-Shen C., Shen M.M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461:495-500.
150. Wang Y., Xue H., Cutz J.C., Bayani J., Mawji N.R., Chen W.G., Goetz L.J., Hayward S.W., Sadar M.D., Gilks C.B., Gout P.W., Squire J.A., Cunha G.R., Wang Y.Z. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab. Invest. 2005, 85:1392-1404.
151. Whitson J.M., Carroll P.R. Active surveillance for early-stage prostate cancer: defining the triggers for intervention. J. Clin. Oncol. 2010, 28:2807-2809.
152. Williams T.M., Hassan G.S., Li J., Cohen A.W., Medina F., Frank P.G., Pestell R.G., Di Vizio D., Loda M., Lisanti M.P. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J. Biol. Chem. 2005, 280:25134-25145.
153. Wu C.T., Altuwaijri S., Ricke W.A., Huang S.P., Yeh S., Zhang C., Niu Y., Tsai M.Y., Chang C. Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12679-12684.
154. Wu X., Wu J., Huang J., Powell W.C., Zhang J., Matusik R.J., Sangiorgi F.O., Maxson R.E., Sucov H.M., Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 2001, 101:61-69.
155. Xie X., Luo Z., Slawin K.M., Spencer D.M. The EZC-prostate model: noninvasive prostate imaging in living mice. Mol. Endocrinol. 2004, 18:722-732.
156. Yan Y., Sheppard P.C., Kasper S., Lin L., Hoare S., Kapoor A., Dodd J.G., Duckworth M.L., Matusik R.J. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 1997, 32:129-139.
157. You M.J., Castrillon D.H., Bastian B.C., O'Hagan R.C., Bosenberg M.W., Parsons R., Chin L., DePinho R.A. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1455-1460.
158. Yu S., Yeh C.R., Niu Y., Chang H.C., Tsai Y.C., Moses H.L., Shyr C.R., Chang C., Yeh S. Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts. Prostate 2012, 72:437-449.
159. Yu S., Zhang C., Lin C.C., Niu Y., Lai K.P., Chang H.C., Yeh S.D., Chang C., Yeh S. Altered prostate epithelial development and IGF-1 signal in mice lacking the androgen receptor in stromal smooth muscle cells. Prostate 2011, 71:517-524.
160. Yuan T.C., Veeramani S., Lin M.F. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr. Relat. Cancer 2007, 14:531-547.
161. Zhang J., Thomas T.Z., Kasper S., Matusik R.J. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000, 141:4698-4710.
162. Zhang W., Zhu J., Efferson C.L., Ware C., Tammam J., Angagaw M., Laskey J., Bettano K.A., Kasibhatla S., Reilly J.F., Sur C., Majumder P.K. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res. 2009, 69:7466-7472.
163. Zhang X., Chen M.W., Ng A., Ng P.Y., Lee C., Rubin M., Olsson C.A., Buttyan R. Abnormal prostate development in C3(1)-bcl-2 transgenic mice. Prostate 1997, 32:16-26.
164. Zhang X., Lee C., Ng P.Y., Rubin M., Shabsigh A., Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate 2000, 43:278-285.
165. Zhou Z., Flesken-Nikitin A., Corney D.C., Wang W., Goodrich D.W., Roy-Burman P., Nikitin A.Y. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res. 2006, 66:7889-7898.
166. Zhu C., Luong R., Zhuo M., Johnson D.T., McKenney J.K., Cunha G.R., Sun Z. Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. J. Biol. Chem. 2011, 286:33478-33488.